2013年 · 第48卷第02期

Placenta previa is a common complication in late pregnancy, and the condition is prone to sudden aggravation and endangering the safety of mother and child. Therefore, early diagnosis and correct management are of great significance. At present, there are differences in the diagnosis and treatment of placenta previa at home and abroad, and there is a lack of perfect evidence-based medical evidence for the diagnosis and treatment of placenta previa in China. Therefore, according to the guidelines on the diagnosis and treatment of placenta previa in many countries, as well as the latest evidence-based medical evidence, and combined with the actual clinical work in China, the Obstetrics Group of Obstetrics and Gynecology Branch of Chinese Medical Association organized relevant domestic experts to formulate the "Clinical Diagnosis and Treatment Guidelines of Placenta Previa". The purpose of this guideline is to standardize and guide obstetricians and gynecologists to make reasonable clinical decisions on the diagnosis and treatment of placenta previa. When targeting specific patients, clinicians can comprehensively evaluate the patient's condition and formulate reasonable diagnosis and treatment plans on the basis of referring to this guideline. This guide will be continuously updated as relevant research findings and evidence-based medicine are refined.

The main diagnostic basis of hepatitis B virus (HBV) infection is HBsAg positivity. Mother-to-child transmission is the main cause of chronic HBV infection in China, so the prevention of infants and young children is emphasized. All pregnant women need prenatal screening for hepatitis B serological markers (commonly known as hepatitis B two and a half). If pregnant women are positive for HBsAg, their newborns are at high risk of HBV infection. In addition to hepatitis B vaccine, they must be injected with hepatitis B immunoglobulin (HBIG) within 12 hours after birth. In order to standardize the preventive measures of mother-to-child transmission of HBV in China and reasonably prevent neonatal HBV infection, experts in infectious diseases and obstetrics jointly formulated this guide according to the recognized research results at home and abroad and with reference to relevant data from other countries.

With the aging of society, the number of people entering menopause is getting larger and larger. According to a United Nations survey, 157 million women were aged 45-64 by 2011, and 197 million are expected by 2020^[1]。 As people pay more and more attention to their quality of life, the proportion of people in menopausal transition and postmenopause seeking medical treatment due to irregular menstruation or menopause-related symptoms is gradually increasing, and as far as current treatment methods are concerned, hormone supplementation therapy (HRT) is the most effective scheme to relieve menopause-related symptoms. According to this demand, the Menopause Group of Obstetrics and Gynecology Branch of Chinese Medical Association formulated the "Guidelines for Clinical Application of HRT in Menopausal Transition and Late Menopause" (abbreviated as the Guidelines), which was updated and revised twice. However, in the actual implementation of the guidelines, it was found that the current situation in China is that clinicians still lack experience in the rational application of HRT, and the existing reference literature is mostly based on relevant research, lacking guiding significance for clinical practice, and cannot comprehensively cover the clinical Diversified patient demands. Therefore, there is an increasing demand for standardized diagnosis and treatment procedures that are instructive for clinical operation and can systematically and comprehensively introduce HRT. After discussion by all members of the menopause group of the Obstetrics and Gynecology Branch of the Chinese Medical Association, a standardized diagnosis and treatment process for menopause-related HRT has been drawn up, aiming to provide clinicians with a standardized diagnosis and treatment process for HRT that is in line with Chinese clinical practice and has strong operability.

The development of pelvic floor reconstruction surgery is changing with each passing day, but this kind of surgery has blind spots, which is a complicated level IV operation in obstetrics and gynecology surgery. Therefore, it is urgent to establish a strict training system for pelvic floor reconstruction surgery, and to demonstrate the qualification and quality control of surgeons. At the end of 2011, the American Gynecological Urological Association put forward specific requirements and regulations for the training and qualification of surgeons who perform transvaginal mesh implantation for pelvic organ prolapse (POP). The following is an interpretation of the guide, which is convenient for Chinese obstetrics and gynecology colleagues to learn from.